Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey

dc.contributor.authorOzbey, Ulku
dc.contributor.authorTug, Esra
dc.contributor.authorNamli, Mustafa
dc.date.accessioned2026-08-12T17:45:56Z
dc.date.issued2009
dc.departmentFırat Üniversitesi
dc.description.abstractSchizophrenia is one of the most severe psychiatric disorders, with a worldwide incidence of 1%. Immunological abnormalities have been found to be associated with schizophrenia for decades. Cytokines are key proteins involved in the immune system activation. Interleukin-10 (IL-10), an important immunoregulatory cytokine, is located on chromosome 1q31 32, a region previously reported to be linked to schizophrenia in genetic studies. In the present study it was aimed to examine the IL-10 gene promoter region's polymorphic variants in patients with schizophrenia in a population of the Elazig Region of East Anatolia, Turkey. Polymorphisms at position -1082, -819 and -592 in the IL-10 promoter region were determined in 171 Turkish patients who were diagnosed with schizophrenia, based on the DSM-IV, and 168 healthy controls, by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP). We analyzed allele, genotype, and haplotype distributions using a case-control association study. Genotyping was performed by RFLP. Statistically significant differences were observed in both allelic and genotypic frequencies of the -592A/C polymorphism (Allele, P = 0.034, OR = 1.26, 95% CI 1.02 - 1.56; Genotype, P = 0.048), while the other two polymorphisms in distribution of the alleles and genotypes in patients with schizophrenia were not significantly different from those of controls (P > 0.05). Our results show a significant increase of GTA homozygotes (the high IL-10-producing haplotype) in schizophrenic patients compared to control subjects (P = 0.0001). These data suggest that the IL-10 gene promoter polymorphism may be one of the susceptibility factors to develop schizophrenia in the Turkish population, and apparently in all humans.
dc.identifier.doi10.1080/15622970802626580
dc.identifier.endpage468
dc.identifier.issn1562-2975
dc.identifier.issn1814-1412
dc.identifier.issue4
dc.identifier.orcid0000-0001-9778-4216
dc.identifier.orcid0009-0004-4394-7285
dc.identifier.pmid19153889
dc.identifier.scopus2-s2.0-77449129201
dc.identifier.scopusqualityQ1
dc.identifier.startpage461
dc.identifier.urihttps://doi.org/10.1080/15622970802626580
dc.identifier.urihttps://hdl.handle.net/11508/60886
dc.identifier.volume10
dc.identifier.wosWOS:000273003200015
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofWorld Journal of Biological Psychiatry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectBiological psychiatry
dc.subjectcytokines
dc.subjectgenetics
dc.subjectpolymorphism
dc.subjectschizophrenia
dc.titleInterleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey
dc.typeArticle

Dosyalar